Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jan 7, 2022; 28(1): 140-153
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.140
Figure 2
Figure 2 Cytokine expression between the hepatocellular carcinoma and non-hepatocellular carcinoma groups among chronic hepatitis C patients with advanced fibrosis. A: Tumor necrosis factor-α; B: Tumor necrosis factor-like weak inducer of apoptosis. Δ = (posttreatment cytokine level) - (pretreatment cytokine level). The bar represents the means ± SE. The P value was tested by the Mann–Whitney U test. HCC: Hepatocellular carcinoma; TNF-α: Tumor necrosis factor-α; TWEAK: TNF-like weak inducer of apoptosis; IFN: Interferon; Pre-Tx: Pretreatment; Post-Tx: Posttreatment.

  • Citation: Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol 2022; 28(1): 140-153
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i1/140.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i1.140